All articles tagged with #hair loss
Early mouse research shows the natural sugar 2-deoxy-D-ribose (2dDR) may stimulate hair regrowth by boosting blood vessel growth around hair follicles, a potential new approach for male-pattern baldness that could complement existing drugs like minoxidil; findings are preliminary, with human timelines unclear, but the sugar’s availability and delivery options make it a promising avenue for future study.
As GLP-1 weight-loss drugs grow popular, some users experience temporary hair shedding, prompting a new wave of at-home hair-care products and scalp treatments. The trend is rising quickly: roughly 13% of U.S. adults use GLP-1 meds, with projections of 25 million on them by 2030, and Circana finds GLP-1 households spend more on beauty. Brands from Ulta to Redken, Nutrafol, and KeraFactor are expanding targeted offerings, while doctors note hair recovery varies and depends on nutrition and time, suggesting consumer loyalty as results take months to appear.
Biotin, a popular supplement for hair regrowth, can interfere with lab tests used to monitor cancer treatment, causing falsely high/low results and potentially delaying or altering therapy. Doctors advise stopping biotin at least 72 hours before blood tests; for hair loss management, FDA-approved topical minoxidil is a safer alternative. Many patients take biotin without realizing the risk, and clinicians urge discussing hair-loss strategies with oncologists.
Veradermics’ oral minoxidil candidate VDPHL01 posted positive Phase II/III results for mild-to-moderate pattern hair loss, with 79% (single-dose 8.5 mg daily) and 86% (twice-daily) showing significant hair growth versus 36% on placebo, and a safety profile similar to placebo. If approved, it would be the first new oral treatment for pattern baldness in about 30 years, offering a non-hormonal option with an extended-release design to minimize cardiovascular risks.
Veradermics announced that its oral hair-loss medicine VDPHL01 significantly boosted hair growth in a six-month late-stage trial, with men on the drug gaining 30–33 more hairs per cm² versus about 7 in the placebo; 79–86% of participants and 72–84% of investigators reported improvement, signaling promising efficacy for the therapy.
Vanessa Hudgens opened up in an Instagram Story about postpartum hair loss, describing it as a real but temporary effect of childbirth; experts note shedding often starts a few months after birth and typically resolves within about a year. The High School Musical alum, married to Cole Tucker, has two children—born in July 2024 and November 2025—and she’s learning to embrace her natural hair texture, often styling it in a slicked-back bun as part of mom life.
Pumpkin seed oil, rich in essential fatty acids and antioxidants, may support scalp health and hair follicle function and could help prevent hair thinning by phytosterols inhibiting the enzyme that converts testosterone to DHT. While small studies show promising results, it’s not as potent as medical DHT blockers, so it should be used as part of a broader hair-care routine. Visible results typically take about 3–6 months, and you should consider allergies and any medications before use.
A rising, non-surgical option called platelet-rich plasma (PRP) therapy uses a patient’s own blood to boost hair regrowth and is pitched as a faster, cheaper alternative to hair transplants (roughly $1,200–$3,500 per session, with some patients needing yearly or quarterly sessions). Beverly Hills doctors say PRP can take about 45 minutes and feel like a “lunchtime” procedure, though they frame it as a base treatment to be combined with other therapies rather than a replacement for transplants. With transplants potentially costing $30,000–$50,000, PRP is attracting interest as an affordable first step for those seeking natural-looking hair restoration.
A long-used hair-loss and prostate drug, finasteride, may lower cholesterol and reduce heart-disease risk, per observational human data and mice experiments. While findings are intriguing, the high-dose mouse results may not translate to humans, and potential side effects exist; further clinical trials are needed to confirm heart-health benefits and safe usage.
Scientists have grown fully developed, functional hair follicles in the lab by adding a third cell type—accessory mesenchymal cells—alongside epithelial stem cells and dermal papilla cells. This three-cell recipe enables follicles to mature and cycle like natural hair, with potential implications for hair restoration and broader regenerative medicine, though translating the approach to humans remains a key challenge.
A Japan-led team identified a previously unknown “third cell” required to fully regenerate hair follicles and demonstrated a complete hair-growth cycle in mice by adding this cell to two existing follicle components, signaling potential new therapies for hair loss.
A review suggests Polygonum multiflorum, a traditional Chinese medicinal root, may help androgenetic alopecia by acting on multiple pathways—reducing DHT effects, protecting follicles from damage, activating growth signals such as Wnt and Shh, and improving scalp blood flow—offering a potential alternative to current meds, though more high-quality clinical trials are needed to confirm safety and optimal use.
A hair-loss guide highlighting minoxidil’s role and five top men’s products: Ulo Minoxidil + Tretinoin Plus (7% minoxidil), Men’s Rogaine 5% Minoxidil Foam, Happy Head Oral Minoxidil, RootStim 5% Minoxidil Spray, and hims Topical Finasteride & Minoxidil Spray. The piece notes 5% minoxidil as the FDA-approved starting dose, with options for higher concentrations; results typically appear after 2–6 months, and potential side effects include scalp irritation, temporary shedding, and, for oral minoxidil, cardiovascular risks. It also covers differences between topical and oral forms and encourages consults with a dermatologist for personalized guidance.
The Healthline piece surveys current and prospective hair‑loss treatments, highlighting established options finasteride and minoxidil as effective, affordable therapies, noting three FDA‑approved JAK inhibitors (Olumiant, Litfulo, Leqselvi) for alopecia areata with safety warnings, and surveying emerging approaches such as clascoterone, PP405, ET-02, stem-cell therapies, and fatty‑acid treatments. While these newer options show promise, many are still in early trials, and long‑term durability and safety remain uncertain. Experts emphasize early intervention and consulting ABHRS‑certified physicians for accurate diagnosis and personalized treatment planning.
By comparing 62 mammal genomes, researchers found humans still carry fur genes, but regulatory switches turned them off; this convergent evolution of hairlessness across mammals sheds light on potential hair-loss therapies.